Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up
Journals
European Neuropsychopharmacolo...
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
#1
JOURNAL ARTICLE
Helena Voetterl, Uri Alyagon, Victoria J Middleton, Jonathan Downar, Abraham Zangen, Alexander T Sack, Hanneke van Dijk, Aimee Halloran, Nancy Donachie, Martijn Arns
Both 10 Hz repetitive transcranial magnetic stimulation (rTMS) as well as 18 Hz deep TMS (dTMS) constitute effective, FDA-approved TMS treatment protocols for depression. However, not all patients experience sufficient symptom relief after either of these protocols. Biomarker-guided treatment stratification could aid in personalizing treatment and thereby enhancing improvement. An individual alpha frequency (iAF)-based EEG-biomarker, Brainmarker-I, can differentially stratify patients to depression treatments...
October 11, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
#2
JOURNAL ARTICLE
Alberto Aedo
No abstract text is available yet for this article.
September 28, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
#3
JOURNAL ARTICLE
Weijian Liu, Jurjen Heij, Shu Liu, Luka Liebrand, Matthan Caan, Wietske van der Zwaag, Dick J Veltman, Lin Lu, Moji Aghajani, Guido van Wingen
Accumulating evidence points to imbalanced dopamine (DA) signaling and circulating levels in the pathophysiology of major depressive disorder (MDD). However, the use of conventional MRI scanners and acquisition techniques has prevented a thorough examination of DA neural pathways in MDD. We uniquely employed ultra-high field diffusion MRI at 7.0 Tesla to map the white matter architecture and integrity of several DA pathways in MDD patients. Fifty-three MDD patients and 12 healthy controls (HCs) were enrolled in the final analysis...
September 27, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
#4
LETTER
Cornelis F Vos, Marieke J H Coenen, Sophie E Ter Hark, Rob E Aarnoutse, Arnt F A Schellekens, Joost G E Janzing
No abstract text is available yet for this article.
September 27, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
#5
JOURNAL ARTICLE
Christian Núñez, Christian Stephan-Otto, Alexandra Roldán, Eva Mª Grasa, Mª José Escartí, Eduardo J Aguilar García-Iturrospe, Gracián García-Martí, Maria de la Iglesia-Vaya, Juan Nacher, Maria J Portella, Iluminada Corripio
The study of brain gyrification may provide useful information on the cytoarchitecture and connectivity of the brain. One of the methods that have been developed to estimate brain gyrification, known as surface ratio (SR), has not yet been studied in schizophrenia. Here we aimed to assess whether SR could provide new insights on the brain structure of schizophrenia patients and the severity of symptoms. We also computed a more established brain gyrification measure, namely absolute mean curvature (AMC). We analyzed 63 magnetic resonance images, 25 from schizophrenia patients with treatment-resistant auditory verbal hallucinations (SCH-H), 18 from schizophrenia patients without hallucinations (SCH-NH), and 20 from healthy controls (HC)...
September 27, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
#6
JOURNAL ARTICLE
Martien J H Kas, Steven Hyman, Leanne M Williams, Diego Hidalgo-Mazzei, Quentin J M Huys, Matthew Hotopf, Bruce Cuthbert, Cathryn M Lewis, Livia J De Picker, Paris A Lalousis, Amit Etkin, Gemma Modinos, Hugh M Marston
Current nosology claims to separate mental disorders into distinct categories that do not overlap with each other. This nosological separation is not based on underlying pathophysiology but on convention-based clustering of qualitative symptoms of disorders which are typically measured subjectively. Yet, clinical heterogeneity and diagnostic overlap in disease symptoms and dimensions within and across different diagnostic categories of mental disorders is huge. While diagnostic categories provide the basis for general clinical management, they do not describe the underlying neurobiology that gives rise to individual symptomatic presentations...
September 27, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
#7
JOURNAL ARTICLE
Marco Solmi, Trevor Thompson, Samuele Cortese, Andrés Estradé, Agorastos Agorastos, Joaquim Radua, Elena Dragioti, Davy Vancampfort, Lau Caspar Thygesen, Harald Aschauer, Monika Schlögelhofer, Elena Aschauer, Andres Schneeberger, Christian G Huber, Gregor Hasler, Philippe Conus, Kim Q Do Cuénod, Roland von Känel, Gonzalo Arrondo, Paolo Fusar-Poli, Philip Gorwood, Pierre-Michel Llorca, Marie-Odile Krebs, Elisabetta Scanferla, Taishiro Kishimoto, Golam Rabbani, Karolina Skonieczna-Żydecka, Paolo Brambilla, Angela Favaro, Akihiro Takamiya, Leonardo Zoccante, Marco Colizzi, Julie Bourgin, Karol Kamiński, Maryam Moghadasin, Soraya Seedat, Evan Matthews, John Wells, Emilia Vassilopoulou, Ary Gadelha, Kuan-Pin Su, Jun Soo Kwon, Minah Kim, Tae Young Lee, Oleg Papsuev, Denisa Manková, Andrea Boscutti, Cristiano Gerunda, Diego Saccon, Elena Righi, Francesco Monaco, Giovanni Croatto, Guido Cereda, Jacopo Demurtas, Natascia Brondino, Nicola Veronese, Paolo Enrico, Pierluigi Politi, Valentina Ciappolino, Andrea Pfennig, Andreas Bechdolf, Andreas Meyer-Lindenberg, Kai G Kahl, Katharina Domschke, Michael Bauer, Nikolaos Koutsouleris, Sibylle Winter, Stefan Borgwardt, Istvan Bitter, Judit Balazs, Pál Czobor, Zsolt Unoka, Dimitris Mavridis, Konstantinos Tsamakis, Vasilios P Bozikas, Chavit Tunvirachaisakul, Michael Maes, Teerayuth Rungnirundorn, Thitiporn Supasitthumrong, Ariful Haque, Andre R Brunoni, Carlos Gustavo Costardi, Felipe Barreto Schuch, Guilherme Polanczyk, Jhoanne Merlyn Luiz, Lais Fonseca, Luana V Aparicio, Samira S Valvassori, Merete Nordentoft, Per Vendsborg, Sofie Have Hoffmann, Jihed Sehli, Norman Sartorius, Sabina Heuss, Daniel Guinart, Jane Hamilton, John Kane, Jose Rubio, Michael Sand, Ai Koyanagi, Aleix Solanes, Alvaro Andreu-Bernabeu, Antonia San José Cáceres, Celso Arango, Covadonga M Díaz-Caneja, Diego Hidalgo-Mazzei, Eduard Vieta, Javier Gonzalez-Peñas, Lydia Fortea, Mara Parellada, Miquel A Fullana, Norma Verdolini, Eva Andrlíková, Karolina Janků, Mark J Millan, Mihaela Honciuc, Anna Moniuszko-Malinowska, Igor Łoniewski, Jerzy Samochowiec, Łukasz Kiszkiel, Maria Marlicz, Paweł Sowa, Wojciech Marlicz, Georgina Spies, Brendon Stubbs, Joseph Firth, Sarah Sullivan, Asli Enez Darcin, Hatice Aksu, Nesrin Dilbaz, Onur Noyan, Momoko Kitazawa, Shunya Kurokawa, Yuki Tazawa, Alejandro Anselmi, Cecilia Cracco, Ana Inés Machado, Natalia Estrade, Diego De Leo, Jackie Curtis, Michael Berk, Andre F Carvalho, Philip Ward, Scott Teasdale, Simon Rosenbaum, Wolfgang Marx, Adrian Vasile Horodnic, Liviu Oprea, Ovidiu Alexinschi, Petru Ifteni, Serban Turliuc, Tudor Ciuhodaru, Alexandra Bolos, Valentin Matei, Dorien H Nieman, Iris Sommer, Jim van Os, Therese van Amelsvoort, Ching-Fang Sun, Ta-Wei Guu, Can Jiao, Jieting Zhang, Jialin Fan, Liye Zou, Xin Yu, Xinli Chi, Philippe de Timary, Ruud van Winkel, Bernardo Ng, Edilberto Peña de León, Ramon Arellano, Raquel Roman, Thelma Sanchez, Larisa Movina, Pedro Morgado, Sofia Brissos, Oleg Aizberg, Anna Mosina, Damir Krinitski, James Mugisha, Dena Sadeghi-Bahmani, Farshad Sheybani, Masoud Sadeghi, Samira Hadi, Serge Brand, Antonia Errazuriz, Nicolas Crossley, Dragana Ignjatovic Ristic, Carlos López-Jaramillo, Dimitris Efthymiou, Praveenlal Kuttichira, Roy Abraham Kallivayalil, Afzal Javed, Muhammad Iqbal Afridi, Bawo James, Omonefe Joy Seb-Akahomen, Jess Fiedorowicz, Jeff Daskalakis, Lakshmi N Yatham, Lin Yang, Tarek Okasha, Aïcha Dahdouh, Jari Tiihonen, Jae Il Shin, Jinhee Lee, Ahmed Mhalla, Lotfi Gaha, Takoua Brahim, Kuanysh Altynbekov, Nikolay Negay, Saltanat Nurmagambetova, Yasser Abu Jamei, Mark Weiser, Christoph U Correll
There is no multi-country/multi-language study testing a-priori multivariable associations between non-modifiable/modifiable factors and validated wellbeing/multidimensional mental health outcomes before/during the COVID-19 pandemic. Moreover, studies during COVID-19 pandemic generally do not report on representative/weighted non-probability samples. The Collaborative Outcomes study on Health and Functioning during Infection Times (COH-FIT) is a multi-country/multi-language survey conducting multivariable/LASSO-regularized regression models and network analyses to identify modifiable/non-modifiable factors associated with wellbeing (WHO-5)/composite psychopathology (P-score) change...
September 27, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
#8
JOURNAL ARTICLE
Cristina Ruiz-Rull, María José Jaén-Moreno, Gloria Isabel Del Pozo, Cristina Camacho-Rodríguez, Marta Rodríguez-López, Fernando Rico-Villademoros, José Luis Otero-Ferrer, Nuria Feu, Micaela Reyes-López, Rosa M Fiestas, David Laguna-Muñoz, Ana Jiménez-Peinado, David Mannino, Eduard Vieta, Fernando Sarramea
This prospective observational study aimed to evaluate the rate of change in forced expiratory volume in the first second (FEV1) and to explore the factors associated with changes in FEV1 in people with serious mental illness (SMI). Sixty subjects diagnosed with schizophrenia or bipolar disorder who were smokers and without history of respiratory illness agreed to participate. The mean (range) follow-up period was 3.54 (3.00-4.98) years. The mean (standard deviation) annual rate of change in FEV1 decreased by 39...
September 26, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
#9
JOURNAL ARTICLE
Andreza B Sonego, Douglas S Prado, Daniela L Uliana, Thiago M Cunha, Anthony A Grace, Leonardo B M Resstel
Maternal infection and stress exposure, especially during childhood and adolescence, have been implicated as risk factors for schizophrenia. Both insults induce an exacerbated inflammatory response, which could mediate disturbance of neurodevelopmental processes and, ultimately, malfunctioning of neural systems observed in this disorder. Thus, anti-inflammatory drugs, such as PPARγ agonists, may potentially be used to prevent the development of schizophrenia. Microglia culture was prepared from the offspring of saline or poly(I:C)-injected mice...
September 26, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
#10
JOURNAL ARTICLE
Eduard Vieta, Lidia Ilzarbe
No abstract text is available yet for this article.
September 26, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
#11
JOURNAL ARTICLE
Dina Popovic, Eduard Vieta
No abstract text is available yet for this article.
September 26, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
#12
REVIEW
Daniel Umbricht, Martien J H Kas, Gerard R Dawson
The failure rate of drugs being developed for neuropsychiatric indications remains high. Optimizing drug discovery and development requires not only a better neurobiological understanding of disease aetiology and development, but also the means by which we can measure relevant biological and clinical processes related to disease progression, drug target engagement, and sensitivity to treatment. Here we address the role and key considerations for the selection of biomarkers in clinical drug development for neuropsychiatric disorders...
September 4, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
#13
REVIEW
Dijana Ostojic, Paris Alexandros Lalousis, Gary Donohoe, Derek W Morris
To understand the complex nature of heterogeneous psychiatric disorders, scientists and clinicians are required to employ a wide range of clinical, endophenotypic, neuroimaging, genomic, and environmental data to understand the biological mechanisms of psychiatric illness before this knowledge is applied into clinical setting. Machine learning (ML) is an automated process that can detect patterns from large multidimensional datasets and can supersede conventional statistical methods as it can detect both linear and non-linear relationships...
September 3, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
#14
LETTER
Mary Bunka, Jehannine Austin, Louisa Edwards, Gavin Wong, Stirling Bryan
No abstract text is available yet for this article.
September 3, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
#15
LETTER
Brooke Manning, Amie C Hayley, Luke A Downey
No abstract text is available yet for this article.
September 2, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
#16
LETTER
Rosa Calvo Escalona
No abstract text is available yet for this article.
September 2, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
#17
JOURNAL ARTICLE
Alessandro Miola, Mete Ercis, Vanessa K Pazdernik, Manuel Fuentes Salgado, Javier Ortiz-Orendain, Manuel Gardea-Reséndez, Peggy M Gruhlke, Ian Michel, J Michael Bostwick, Alastair J McKean, Jennifer L Vande Voort, Aysegul Ozerdem, Mark A Frye
This study investigated the impact of prior antidepressant and stimulant exposure on the age at onset (AAO) of first episode mania (FEM) or psychosis (FEP). Patients with FEP and FEM born after 1985 in Olmsted County, Minnesota, were identified using the Rochester Epidemiology Project. Duration and peak dose of antidepressant and stimulant exposure were quantified by review of the electronic health record. Peak doses were converted to defined daily dose (DDD), and cumulative exposure was calculated as DDD multiplied by treatment duration...
September 2, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
#18
LETTER
Muhammad Shaheer Bin Faheem, Ghazal Ishaque
No abstract text is available yet for this article.
September 2, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
#19
LETTER
Michele De Prisco, Vincenzo Oliva
No abstract text is available yet for this article.
September 2, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
#20
JOURNAL ARTICLE
Marion Leboyer, Ryad Tamouza
No abstract text is available yet for this article.
August 31, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
